The WEGOVY market has experienced significant growth, driven by rising obesity rates and increasing demand for effective weight-loss treatments. Novo Nordisk's blockbuster drug has seen strong ...

For older adults with type 2 diabetes, use of GLP-1 RAs is associated with a modestly lower risk for depression compared with DPP-4i use.

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

Terns announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...

GLP-1 receptor agonists like Ozempic, Wegovy and Mounjaro, have gained significant attention for their effectiveness in managing Type 2 diabetes and promoting weight loss. These medications work ...